AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 784 businesses audited.
Medical Devices, Pharma & Biotech BS: RINVOQ (AbbVie Inc.) (rinvoq.com)
This is a low-BS, highly regulated pharmaceutical site where legal necessity forces a high substance-to-signal ratio. The minimal fluff present is confined to consumer-facing metaphors, while the core architecture is a forensic database of clinical and financial specifications. It is a benchmark for accuracy in a high-stakes industry.
To further reduce the BS score, consolidate the massive, repeated ‘USES’ and ‘ISI’ blocks into a single global footer or a sticky navigation element to reduce repetitive character counts. Link the ‘Share your story’ call to action to actual peer-reviewed outcomes or ClinicalTrials.gov results to ground patient experiences in data. Replace vague metaphors like ‘tame symptoms’ in the H1 with more specific clinical endpoints, such as ‘reduce inflammation markers.’ Ensure all H3 tags like ‘On this page’ are converted to substantive descriptors to improve the technical heading hierarchy.
The information density is exceptionally high due to the clinical and regulatory nature of the product, although some marketing fluff exists in the hero sections. Headings like ‘See how RINVOQ helps tame symptoms’ use the power word ‘tame’ to anthropomorphize pharmacological action, but the body text immediately grounds this in substance with specific condition counts and technical descriptions of Janus kinase inhibitors. The ratio of marketing language to substance is skewed heavily toward substance by the inclusion of 15,000-character safety blocks and specific weight-based dosing (e.g., 22 pounds and 66 pounds). However, the score is slightly elevated by the extreme repetition of the ‘USES’ and ‘ISI’ blocks across every page, which, while legally required, increases content volume without adding new information.
When edges drift or clusters collapse, your content becomes a set of disconnected islands. Inspect your internal link topology to identify where authority flow breaks or never forms.
There is virtually zero semantic drift between the homepage signal and the sub-page substance. The homepage H1 promises help for 9 conditions, and the sub-pages deliver granular technical details for those specific therapeutic areas, such as the pJIA and JPsA page. The cost page directly supports the homepage claim of ‘$0 a month’ with a detailed breakdown of Medicare Part D catastrophic phases and Wholesale Acquisition Costs of $7,090.41. The only minor drift is the stylistic transition from the ‘relief’ marketing tone on the homepage to the ‘boxed warning’ severity of the safety pages.
Stop the ROI leak caused by technical debt and strategic misalignment. Conduct an Independent Strategic Diagnosis for 1 Euro to identify high impact issues across all audit categories.
No trust theatre is detected as the trust_theatre_flag is false across all pages. While a review_count of 1 is present in the schema, the site does not rely on unverifiable patient testimonials or ‘as seen on’ logos. All clinical claims are backed by an external proof path leading to the full Prescribing Information and Medication Guide, which are the highest form of industry-standard verification.
The proof density is robust, with a ratio of approximately 10 verifiable clinical/financial data points for every 1 marketing assertion. Specific evidence includes the $7,090.41 Wholesale Acquisition Cost dated January 2026 and the exact milligram concentrations for extended-release tablets (15 mg, 30 mg, 45 mg). Vague assertions are minimized to facilitate a direct path to the FDA-approved labeling.
To evaluate URL identity stability and multilingual coherence, review the Yoast Identity Stability audit. View the Yoast Identity Stability Audit for a practical example of canonical alignment and language layer integrity.
The site avoids most commodity fingerprints by virtue of its highly specific medical positioning. The value proposition of being the ‘first and only oral JAK’ for pediatric JIA is a unique identifier that cannot be copy-pasted onto a competitor’s site. Cliché usage is limited to phrases like ‘stand up to your condition’ and ‘tame symptoms,’ which are mild compared to industry averages. Boilerplate sections like ‘Leaving AbbVie Web Site’ are functional and regulatory, rather than generic marketing filler.
Authority is firmly established through the AbbVie brand and technical metadata. The schema_json identifies the specialty as Rheumatology and properly attributes the content to AbbVie Inc. as the manufacturer. There are no claims of ‘world-class experts’ that lack a digital footprint; the drug’s FDA approval status serves as the primary authority signal, which is verifiable through official government databases.
The marketing tone of ‘relief is possible’ is strictly reconciled with the clinical reality of the product. Every performance claim, such as the ability to ‘tame symptoms,’ is immediately countered by the specific risks listed in the Boxed Warning, including serious infections and cardiovascular events. This transparency between marketing promise and pharmacological risk prevents a performance disconnect.
Medical Devices, Pharma & Biotech BS: RINVOQ (AbbVie Inc.) (rinvoq.com)
The content perfectly aligns with the Pharmaceutical and Biotech industry standards, specifically focusing on a prescription JAK inhibitor. All pages contain the requisite FDA-mandated safety disclosures, indication lists, and prescribing information links typical of a regulated therapeutic product.
When your canonical, redirect, and final URL disagree, the model treats each version as a separate entity. Study the Canonical Integrity Framework Guide and see why stable identity is the prerequisite for AI driven retrieval.
“The score of 11 is primarily driven by the 'Information Density' pillar, specifically the high volume of verbatim content repetition across sub-pages and the use of marketing power words in primary headings. The 'Semantic Coherence' pillar contributed a minor 2 points due to some structural heading inconsistencies. All other trust and authority pillars scored 0 or 1, as the site provides nearly 100% verifiable evidence for its claims.”
Analysis Disclosure & Source Attribution
Snapshot Date: June 19, 2026
Purpose: This data is presented under “Fair Use” / “Educational Exception” for the purpose of forensic semantic analysis, allowing users to see how machine logic interprets digital signals.
Machine Perception Notice: This evaluation is generated by machine-read logic (MRL). The AI interprets the “Digital Ghost” of a website (code, metadata, and semantic structures), which may differ from what a human sees at the same moment. This is an automated technical diagnostic and not a statement of fact or human opinion regarding the real-world integrity or legitimacy of the business. Any missing or inaccessible elements in the snapshot are treated as machine-read signals, reflecting AI rendering limitations rather than intentional omission.
Notice to the Evaluated Business: This analysis is part of a non-adversarial audit. The results are intended as professional feedback to help improve machine-readability and authority signals. Any company can use these insights for free. When content is updated, a fresh audit can be requested at any time to reflect the current state.
To All Users: You are encouraged to visit the live site at RINVOQ (AbbVie Inc.) to view the most current version of their content and see directly what the company offers.